CA
NZ
UK
AU
IND
US
Aligos Therapeutics, Inc. (NASDAQ:ALGS) shares moved higher in pre-market trading after the company confirmed that pevifoscorvir sodium, its lead hepatitis B candidate, received Breakthrough Therapy Designation from the Center for Drug Evaluation of China's National Medical Products Administration. Aligos is a clinical-stage biopharmaceutical company …
Context Therapeutics Inc. (NASDAQ:CNTX) shares moved higher in pre-market trading after the company confirmed its addition to the Russell 2000 and Russell 3000 indexes, a change that took effect following the annual reconstitution process. Context Therapeutics is a clinical-stage biopharmaceutical company headquartered in Philadelphia …
Getty Images Holdings, Inc. (NYSE:GETY) shares declined in pre-market trading after the company delivered formal written notice terminating its merger agreement with Shutterstock, Inc. The termination followed the passage of the merger agreement's extended end date and the company's board decision not to proceed …
Genmab A/S (NASDAQ:GMAB) shares moved higher in pre-market trading after the European Commission granted marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma. Genmab is a Copenhagen, Denmark-based biotechnology company focused on developing antibody …
International Business Machines Corporation (NYSE:IBM) shares continued climbing in pre-market trading, building on Monday's 3.45% close to reach a sixth consecutive session of gains. The momentum has been driven in part by a bullish note from Bank of America, which raised its price target …
The period's scale was concentrated in a small number of landmark offerings rather than spread evenly across the calendar. Nasdaq hosted seven of the year's ten largest initial public offerings, an unusually high share that points to large-capital issuers converging on a single venue …
Tempus AI gained as its clinical AI data platform expanded genomic data library partnerships with oncology-focused pharmaceutical companies and health systems. The multimodal healthcare data moat and oncology genomics testing revenue provide near-term visibility while AI licensing builds.Key HighlightsOncology Genomics Testing Near-Term Revenue:Revenue from …
ResMed rallied on above-average volume after Morgans reiterated its Buy at A$41.72, citing the 16x forward earnings valuation as the lowest since the post-GFC era despite consensus double-digit EPS growth forecasts. Q4 FY2026 earnings on August 6 provide a near-term catalyst checkpoint.Key HighlightsPost-GFC Low …
Recursion Pharmaceuticals advanced as AI-driven drug discovery pipeline progress provided evidence the computational approach generates candidates at scale validating the platform premise. The Bayer strategic partnership provides capital and commercial validation from one of the world's largest pharmaceutical companies.Key HighlightsAI Drug Discovery Pipeline Validation:Progress …
The Logistics Problem That NV-387 Solves
Please wait processing your request...